---
document_datetime: 2025-12-02 06:20:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nyxoid.html
document_name: nyxoid.html
version: success
processing_time: 0.1211171
conversion_datetime: 2025-12-27 23:24:01.876786
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nyxoid

[RSS](/en/individual-human-medicine.xml/66211)

##### Authorised

This medicine is authorised for use in the European Union

naloxone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nyxoid](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77163)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Nyxoid. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Nyxoid.

For practical information about using Nyxoid, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Nyxoid and what is it used for?

Nyxoid is a medicine used for emergency treatment in case of known or suspected overdose of opioid drugs (such as heroin or morphine).

Signs of overdose include pinpoint pupils, abnormally slow and irregular breathing, severe sleepiness and unresponsiveness to touch or loud noises. Nyxoid can be used in adults and adolescents from 14 years of age. It contains the active substance naloxone.

Nyxoid is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, but is given in a different way. While the reference medicine Naloxon HCl B. Braun is given by injection, Nyxoid is given as a spray into the nose.

## How is Nyxoid used?

Nyxoid is a nasal spray available in single-dose containers (1.8 mg). The recommended dose is one spray into one nostril given immediately on suspecting an opioid overdose and while awaiting emergency services; if the first dose does not have an effect, a second dose should be given after 2-3 minutes in the other nostril. If the first dose works well but the patient later worsens a second dose should be given immediately in the other nostril.

For further information, see the package leaflet.

The medicine can only be obtained with a prescription.

## How does Nyxoid work?

The active substance in Nyxoid, naloxone, counteracts the effects of opioid drugs. Opioids work by attaching to and activating opioid receptors (targets) in the body. Naloxone rapidly blocks these receptors, ending the opioid's effects such as slow breathing.

## What benefits of Nyxoid have been shown in studies?

Naloxone, the active substance in Nyxoid, has been widely used in emergency medicine since the 1970s to treat opioid overdose. The company provided data from the published literature showing that naloxone is effective in treating opioid overdose when given by injection (the standard treatment for opioid overdose) as well as into the nose. In addition, a study involving 38 healthy volunteers showed that, when given by a healthcare professional, Nyxoid 2 mg given as a spray into the nose produced a similar level of naloxone in the body as naloxone given in the usual dose of 0.4 mg by injection into a muscle.

## What are the risks associated with Nyxoid?

The most common side effect with Nyxoid (which may affect more than 1 in 10 people) is nausea (feeling sick). Typical opioid withdrawal syndrome is expected after Nyxoid is given to people addicted to opioids; symptoms include restlessness, agitation, feeling or being sick, a fast heart rate and sweating.

For the full list of all side effects and restrictions with Nyxoid, see the package leaflet.

## Why is Nyxoid approved?

The safety and effectiveness of naloxone as an antidote for opioid overdose are well known. Compared with emergency treatments for opioid overdose given by injection, Nyxoid can be given by people with no medical training because it is sprayed into the nose. There is also no risk of needle injury with Nyxoid, and this could encourage members of the public to provide treatment promptly. Therefore, the European Medicines Agency decided that Nyxoid's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Nyxoid?

The company that markets Nyxoid will issue educational materials, including a video, for healthcare professionals and for patients with detailed information on how to use the medicine. The company will also conduct a study on the effectiveness of Nyxoid when given by people with no medical training.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nyxoid have also been included in the summary of product characteristics and the package leaflet.

## Other information about Nyxoid

The European Commission granted a marketing authorisation valid throughout the European Union for Nyxoid on 10 November 2017.

For more information about treatment with Nyxoid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Nyxoid : EPAR - Summary for the public

Reference Number: EMA/626193/2017

English (EN) (74.61 KB - PDF)

**First published:** 12/12/2017

**Last updated:** 12/12/2017

[View](/en/documents/overview/nyxoid-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-88)

български (BG) (101.25 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/bg/documents/overview/nyxoid-epar-summary-public_bg.pdf)

español (ES) (75.19 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/es/documents/overview/nyxoid-epar-summary-public_es.pdf)

čeština (CS) (99.68 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/cs/documents/overview/nyxoid-epar-summary-public_cs.pdf)

dansk (DA) (74.13 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/da/documents/overview/nyxoid-epar-summary-public_da.pdf)

Deutsch (DE) (75.78 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/de/documents/overview/nyxoid-epar-summary-public_de.pdf)

ελληνικά (EL) (102.83 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/el/documents/overview/nyxoid-epar-summary-public_el.pdf)

français (FR) (76.18 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/fr/documents/overview/nyxoid-epar-summary-public_fr.pdf)

hrvatski (HR) (96.48 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/hr/documents/overview/nyxoid-epar-summary-public_hr.pdf)

italiano (IT) (74.3 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/it/documents/overview/nyxoid-epar-summary-public_it.pdf)

latviešu valoda (LV) (96.1 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/lv/documents/overview/nyxoid-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.57 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/lt/documents/overview/nyxoid-epar-summary-public_lt.pdf)

magyar (HU) (93.51 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/hu/documents/overview/nyxoid-epar-summary-public_hu.pdf)

Malti (MT) (101.27 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/mt/documents/overview/nyxoid-epar-summary-public_mt.pdf)

Nederlands (NL) (74.85 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/nl/documents/overview/nyxoid-epar-summary-public_nl.pdf)

polski (PL) (100.75 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/pl/documents/overview/nyxoid-epar-summary-public_pl.pdf)

português (PT) (75.4 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/pt/documents/overview/nyxoid-epar-summary-public_pt.pdf)

română (RO) (97.54 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/ro/documents/overview/nyxoid-epar-summary-public_ro.pdf)

slovenčina (SK) (99.75 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/sk/documents/overview/nyxoid-epar-summary-public_sk.pdf)

slovenščina (SL) (94.9 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/sl/documents/overview/nyxoid-epar-summary-public_sl.pdf)

Suomi (FI) (73.01 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/fi/documents/overview/nyxoid-epar-summary-public_fi.pdf)

svenska (SV) (73.2 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/sv/documents/overview/nyxoid-epar-summary-public_sv.pdf)

Nyxoid : EPAR - Risk-management-plan summary

English (EN) (607.7 KB - PDF)

**First published:** 12/06/2025

[View](/en/documents/rmp-summary/nyxoid-epar-risk-management-plan-summary_en.pdf)

## Product information

Nyxoid : EPAR - Product Information

English (EN) (322.74 KB - PDF)

**First published:** 12/12/2017

**Last updated:** 12/06/2025

[View](/en/documents/product-information/nyxoid-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-81)

български (BG) (417.32 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/bg/documents/product-information/nyxoid-epar-product-information_bg.pdf)

español (ES) (334.31 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/es/documents/product-information/nyxoid-epar-product-information_es.pdf)

čeština (CS) (326.25 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/cs/documents/product-information/nyxoid-epar-product-information_cs.pdf)

dansk (DA) (279.57 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/da/documents/product-information/nyxoid-epar-product-information_da.pdf)

Deutsch (DE) (298.07 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/de/documents/product-information/nyxoid-epar-product-information_de.pdf)

eesti keel (ET) (253.76 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/et/documents/product-information/nyxoid-epar-product-information_et.pdf)

ελληνικά (EL) (378.17 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/el/documents/product-information/nyxoid-epar-product-information_el.pdf)

français (FR) (369.7 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/fr/documents/product-information/nyxoid-epar-product-information_fr.pdf)

hrvatski (HR) (350.55 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/hr/documents/product-information/nyxoid-epar-product-information_hr.pdf)

íslenska (IS) (293.52 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/is/documents/product-information/nyxoid-epar-product-information_is.pdf)

italiano (IT) (300.23 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/it/documents/product-information/nyxoid-epar-product-information_it.pdf)

latviešu valoda (LV) (344.36 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/lv/documents/product-information/nyxoid-epar-product-information_lv.pdf)

lietuvių kalba (LT) (325.43 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/lt/documents/product-information/nyxoid-epar-product-information_lt.pdf)

magyar (HU) (348.96 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/hu/documents/product-information/nyxoid-epar-product-information_hu.pdf)

Malti (MT) (371.33 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/mt/documents/product-information/nyxoid-epar-product-information_mt.pdf)

Nederlands (NL) (302.41 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/nl/documents/product-information/nyxoid-epar-product-information_nl.pdf)

norsk (NO) (297.97 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/no/documents/product-information/nyxoid-epar-product-information_no.pdf)

polski (PL) (472.97 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/pl/documents/product-information/nyxoid-epar-product-information_pl.pdf)

português (PT) (305.21 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/pt/documents/product-information/nyxoid-epar-product-information_pt.pdf)

română (RO) (366.75 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/ro/documents/product-information/nyxoid-epar-product-information_ro.pdf)

slovenčina (SK) (341.57 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/sk/documents/product-information/nyxoid-epar-product-information_sk.pdf)

slovenščina (SL) (334.33 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/sl/documents/product-information/nyxoid-epar-product-information_sl.pdf)

Suomi (FI) (255.08 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/fi/documents/product-information/nyxoid-epar-product-information_fi.pdf)

svenska (SV) (309 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/06/2025

[View](/sv/documents/product-information/nyxoid-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0019 25/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nyxoid : EPAR - All Authorised presentations

English (EN) (43.56 KB - PDF)

**First published:** 12/12/2017

**Last updated:** 12/12/2017

[View](/en/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-596)

български (BG) (71.45 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/bg/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_bg.pdf)

español (ES) (22.63 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/es/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.7 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/cs/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/da/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.71 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/de/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.15 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/et/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (66.85 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/el/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_el.pdf)

français (FR) (22.82 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/fr/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (57.68 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/hr/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (22.37 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/is/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_is.pdf)

italiano (IT) (22.29 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/it/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (68.92 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/lv/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/lt/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.67 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/hu/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67.34 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/mt/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.11 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/nl/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (22.39 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/no/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_no.pdf)

polski (PL) (45.84 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/pl/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_pl.pdf)

português (PT) (22.27 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/pt/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.53 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/ro/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.86 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/sk/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (39.07 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/sl/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.67 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/fi/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.95 KB - PDF)

**First published:**

12/12/2017

**Last updated:**

12/12/2017

[View](/sv/documents/all-authorised-presentations/nyxoid-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nyxoid Active substance naloxone hydrochloride dihydrate International non-proprietary name (INN) or common name naloxone Therapeutic area (MeSH) Opiate Overdose Anatomical therapeutic chemical (ATC) code V03AB15

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings.

Nyxoid is indicated in adults and adolescents aged 14 years and over.

Nyxoid is not a substitute for emergency medical care.

## Authorisation details

EMA product number EMEA/H/C/004325 Marketing authorisation holder

Mundipharma Corporation (Ireland) Limited

United Drug House Magna Drive

Marketing authorisation issued 09/11/2017 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nyxoid : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.98 KB - PDF)

**First published:** 26/03/2025

**Last updated:** 12/06/2025

[View](/en/documents/procedural-steps-after/nyxoid-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Nyxoid : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (396.97 KB - PDF)

**First published:** 05/02/2018

**Last updated:** 26/03/2025

[View](/en/documents/procedural-steps-after/nyxoid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Nyxoid : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/690823/2017

English (EN) (9.75 MB - PDF)

**First published:** 12/12/2017

**Last updated:** 12/12/2017

[View](/en/documents/assessment-report/nyxoid-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Nyxoid

Reference Number: EMA/CHMP/594248/2017

English (EN) (68.8 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 15/09/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-nyxoid_en.pdf)

#### News on Nyxoid

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Nyxoid : EPAR - Product information - tracked changes

English (EN) (557.88 KB - DOCX)

**First published:** 12/06/2025

[View](/en/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_en.docx-0)

[Other languages (24)](#file-language-dropdown-545)

български (BG) (554.77 KB - DOCX)

**First published:**

12/06/2025

[View](/bg/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_bg.docx-0)

español (ES) (542.04 KB - DOCX)

**First published:**

12/06/2025

[View](/es/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_es.docx-0)

čeština (CS) (497.73 KB - DOCX)

**First published:**

12/06/2025

[View](/cs/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_cs.docx-0)

dansk (DA) (425.38 KB - DOCX)

**First published:**

12/06/2025

[View](/da/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_da.docx-0)

Deutsch (DE) (547.85 KB - DOCX)

**First published:**

12/06/2025

[View](/de/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_de.docx-0)

eesti keel (ET) (538.65 KB - DOCX)

**First published:**

12/06/2025

[View](/et/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_et.docx-0)

ελληνικά (EL) (465.67 KB - DOCX)

**First published:**

12/06/2025

[View](/el/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_el.docx-0)

français (FR) (187.42 KB - DOCX)

**First published:**

12/06/2025

[View](/fr/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_fr.docx-0)

hrvatski (HR) (547.3 KB - DOCX)

**First published:**

12/06/2025

[View](/hr/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_hr.docx-0)

íslenska (IS) (550.05 KB - DOCX)

**First published:**

12/06/2025

[View](/is/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_is.docx-0)

italiano (IT) (427.15 KB - DOCX)

**First published:**

12/06/2025

[View](/it/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_it.docx-0)

latviešu valoda (LV) (467.25 KB - DOCX)

**First published:**

12/06/2025

[View](/lv/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_lv.docx-0)

lietuvių kalba (LT) (545.51 KB - DOCX)

**First published:**

12/06/2025

[View](/lt/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_lt.docx-0)

magyar (HU) (550.12 KB - DOCX)

**First published:**

12/06/2025

[View](/hu/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_hu.docx-0)

Malti (MT) (540.47 KB - DOCX)

**First published:**

12/06/2025

[View](/mt/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_mt.docx-0)

Nederlands (NL) (531.86 KB - DOCX)

**First published:**

12/06/2025

[View](/nl/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_nl.docx-0)

norsk (NO) (453.79 KB - DOCX)

**First published:**

12/06/2025

[View](/no/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_no.docx-0)

polski (PL) (538.81 KB - DOCX)

**First published:**

12/06/2025

[View](/pl/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_pl.docx-0)

português (PT) (545.01 KB - DOCX)

**First published:**

12/06/2025

[View](/pt/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_pt.docx-0)

română (RO) (543.23 KB - DOCX)

**First published:**

12/06/2025

[View](/ro/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_ro.docx-0)

slovenčina (SK) (543.37 KB - DOCX)

**First published:**

12/06/2025

[View](/sk/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_sk.docx-0)

slovenščina (SL) (546.23 KB - DOCX)

**First published:**

12/06/2025

[View](/sl/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_sl.docx-0)

Suomi (FI) (536.23 KB - DOCX)

**First published:**

12/06/2025

[View](/fi/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_fi.docx-0)

svenska (SV) (532.8 KB - DOCX)

**First published:**

12/06/2025

[View](/sv/documents/product-information-tracked-changes/nyxoid-epar-product-information-tracked-changes_sv.docx-0)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/06/2025

## Share this page

[Back to top](#main-content)